Related Experiment Video
Updated: Aug 18, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Androgen-independent prostate cancer: not so chemorefractory after all
1Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Abstract:
Historically, hormone-refractory prostate cancer has not been routinely treated with chemotherapy, based on perceptions that single agents were not all that active, this patient population was too fragile to receive such therapy, responses were virtually impossible to verify given the rarity of bidimensionally measurable disease, and, if seen, responses were not clinically meaningful. The "truths" of the 1970s and 1980s are the "myths" of the 1990s, but unfortunately many physicians continue to propagate these myths despite accumulating data to the contrary. Newer combination regimens produce objective response rates in measurable disease that rival those seen in other solid tumors that are uniformly labeled as "chemosensitive." The widespread use of the serum prostate-specific antigen level has allowed the detection of progressive disease at an earlier stage in patients with an excellent performance status. Although chemotherapy to date has not had an impact on patient survival, quality of life analyses have clearly demonstrated improved palliation in treated patients. Hopefully, as this knowledge is disseminated more widely, more patients will be offered cytotoxic therapy for this currently undertreated disease.
Insights
Chemotherapy offers improved palliation for hormone-refractory prostate cancer, challenging historical treatment myths. Newer regimens show objective responses, and prostate-specific antigen testing aids early detection for better patient outcomes.
Area of Science:
- Oncology
- Medical Oncology
- Prostate Cancer Research
Background:
- Historically, hormone-refractory prostate cancer (HRPC) was undertreated with chemotherapy due to perceived low efficacy and patient fragility.
- Outdated perceptions hindered the adoption of chemotherapy despite emerging evidence.
- The rarity of measurable disease historically complicated response assessment in HRPC.
Purpose of the Study:
- To challenge historical myths surrounding chemotherapy for hormone-refractory prostate cancer.
- To highlight the efficacy of newer combination chemotherapy regimens in HRPC.
- To emphasize the benefits of chemotherapy in improving patient quality of life.
Main Methods:
- Review of historical and contemporary data on chemotherapy for HRPC.
- Analysis of objective response rates in patients with measurable HRPC disease.
- Evaluation of quality of life data from treated HRPC patients.
Main Results:
- Newer combination chemotherapy regimens achieve objective response rates comparable to other "chemosensitive" solid tumors.
- Serum prostate-specific antigen (PSA) level monitoring enables earlier detection of disease progression in HRPC.
- While not impacting survival, chemotherapy significantly improves palliation and quality of life for HRPC patients.
Conclusions:
- Chemotherapy is an underutilized but effective treatment option for hormone-refractory prostate cancer.
- Current data refutes historical beliefs about the ineffectiveness and risks of chemotherapy in HRPC.
- Wider dissemination of knowledge on chemotherapy benefits can improve HRPC patient care and palliation.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers